Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the development of AI-driven drug discovery for longevity therapies. The company was incorporated in 2006 and is headquartered in Paris, France.
Frequently asked questions
What sector does Biophytis SA (ALBPS) operate in?
Biophytis SA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Biophytis SA (ALBPS) current stock price?
As of the latest data, Biophytis SA stock price is €0.06, with a previous close of €0.06. Biophytis SA lost -€0.00 in the last trading session, representing a -0.53% loss.
What is Biophytis SA (ALBPS) current market capitalization?
Biophytis SA market cap is approximately 7.82 million.
What is Biophytis SA (ALBPS) Earnings Per Share (EPS)?
The trailing EPS is -€0.34, and the forward EPS is -€2.15.
Does Biophytis SA (ALBPS) pay dividends?
No. Biophytis SA does not pay a dividend.
What is Biophytis SA (ALBPS) beta (volatility) score?
Biophytis SA has a beta of 0.846, meaning its volatility is roughly in line with the market.
